DENTSPLY SIRONA Inc.

DENTSPLY SIRONA Inc. (XRAY) Market Cap

DENTSPLY SIRONA Inc. has a market capitalization of $2.46B.

Financials based on reported quarter end 2025-12-31

Price: $12.31

-0.48 (-3.75%)

Market Cap: 2.46B

NASDAQ · time unavailable

CEO: Daniel T. Scavilla

Sector: Healthcare

Industry: Medical - Instruments & Supplies

IPO Date: 1987-08-12

Website: https://www.dentsplysirona.com

DENTSPLY SIRONA Inc. (XRAY) - Company Information

Market Cap: 2.46B · Sector: Healthcare

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.

Analyst Sentiment

62%
Buy

Based on 31 ratings

Analyst 1Y Forecast: $14.89

Average target (based on 3 sources)

Consensus Price Target

Low

$12

Median

$13

High

$16

Average

$13

Potential Upside: 8.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 DENTSPLY SIRONA INC (XRAY) — Investment Overview

🧩 Business Model Overview

DENTSPLY SIRONA Inc. (ticker: XRAY) is a global leader in dental products and technologies, serving both dental professionals and laboratories. The company offers a comprehensive portfolio that spans dental consumables, equipment, and digital solutions, positioning itself as a full-service partner to the dental health sector. DENTSPLY SIRONA operates through a network that includes original equipment manufacturing, R&D, direct-to-dentist sales, as well as distribution partnerships. Its integration of equipment, consumables, and digital workflow solutions enables dental professionals to perform everything from restorative procedures to image-guided diagnostics and digital orthodontics. The company’s vertically integrated model enhances customer loyalty and allows DENTSPLY SIRONA to address a broad range of clinical needs within the dental care continuum.

💰 Revenue Streams & Monetisation Model

DENTSPLY SIRONA generates revenue through three primary segments: dental consumables, dental technology and equipment, and digital solutions. - **Consumables**: This includes dental anesthetics, restorative materials, endodontics, and preventive products, typically generating recurring revenue through repeat purchases by clinics and labs. - **Equipment and Technology**: Sales of dental chairs, imaging systems, CAD/CAM devices (such as CEREC), and instruments constitute one-off capital expenditures for customers. These categories often carry higher margins, are subject to product cycles, and may have associated aftermarket revenue streams. - **Digital Solutions and Services**: Increasingly, the company monetizes software (such as digital scanning/imaging), cloud-based treatment planning, training, and customer support. These solutions enhance the stickiness of its systems with practitioners and create ongoing service and SaaS-style revenue opportunities. Geographically, DENTSPLY SIRONA drives revenue from a diversified mix across North America, Europe, and emerging markets, balancing regional demand and enhancing resiliency to localized shocks.

🧠 Competitive Advantages & Market Positioning

DENTSPLY SIRONA commands competitive advantages rooted in scale, R&D capability, brand equity, and comprehensive product offerings. As one of the largest global dental solutions providers, the company benefits from economies of scale in manufacturing, distribution, and global procurement. Its strong R&D investment facilitates consistent product innovation, maintaining leadership in areas like CAD/CAM chairside systems and 3D imaging. The company’s portfolio breadth—ranging from single-use consumables to sophisticated diagnostic and treatment systems—enables it to cross-sell and bundle offerings to dental offices seeking end-to-end solutions. Furthermore, DENTSPLY SIRONA’s global footprint and established distribution network provide greater customer access and serve as high barriers to entry for competitors. Strong relationships with dental professionals and robust training/education programs further reinforce loyalty and adoption of proprietary systems.

🚀 Multi-Year Growth Drivers

Several durable growth catalysts underpin DENTSPLY SIRONA’s long-term prospects: - **Digitization and Workflow Integration**: The adoption of digital dentistry (scanning, 3D printing, CAD/CAM restoration, and digital diagnostics) continues to accelerate. DENTSPLY SIRONA, with leading chairside and lab solutions, is well-positioned to drive and capture this transformation. - **Aging Population and Dental Demand**: Global demographic trends, including aging populations and greater awareness of dental health, support rising demand for restorative, preventive, and cosmetic procedures. - **Expansion in Emerging Markets**: Penetration of dental care in developing countries remains relatively low. DENTSPLY SIRONA’s established distribution enables it to benefit from increased healthcare access and rising income levels. - **New Product Launches and R&D**: Ongoing innovation in implants, aligners, imaging, and workflow systems continues to open new addressable markets and enable premium pricing. - **Cross-Selling and Bundling**: Integrated platforms create opportunities for recurring revenue and upselling through solution bundles and ongoing service/support offerings.

⚠ Risk Factors to Monitor

Investors should be mindful of several potential risks: - **Cyclicality and Capital Expenditure Sensitivity**: Large equipment sales can be cyclical, as dental practices sometimes delay purchases during economic downturns. - **Competitive Pressure**: The dental technology space features increasing competition from both global peers and nimble, innovative niche entrants, particularly in digital and software solutions. - **Regulatory and Reimbursement Changes**: Shifting global healthcare regulations, reimbursement frameworks, and product approval processes can impact market access, compliance costs, and innovation pipelines. - **Supply Chain Disruptions**: As a manufacturer with global operations, DENTSPLY SIRONA is exposed to supply chain interruptions, logistic costs, and potential trade barriers. - **Execution Risk in Emerging Markets**: While emerging markets offer growth, operating in less mature regulatory and business environments may introduce volatility and compliance challenges.

📊 Valuation & Market View

DENTSPLY SIRONA is frequently valued both as a healthcare equipment provider and as a consumer healthcare company, resulting in a blended set of valuation multiples that reflect both growth potential and the defensive attributes of dental care. On a relative basis, valuation may be benchmarked against global peers in the dental and broader medical technology spaces, looking at metrics such as enterprise value to EBITDA, price to earnings, and price to free cash flow. The company’s diversified recurring revenue streams from consumables, coupled with higher-margin digital and equipment solutions, create a balanced profile that appeals to growth-oriented and defensive investors. Market sentiment typically rewards DENTSPLY SIRONA for successful execution on digital rollout, new product adoption rates, and margin expansion initiatives. Conversely, concerns about cyclical exposure and competitive dynamics can create periods of valuation discount or volatility.

🔍 Investment Takeaway

DENTSPLY SIRONA presents a compelling investment profile for those seeking exposure to secular trends in global dental care, including digital transformation, demographic tailwinds, and rising procedural complexity. The company’s integrated model, product breadth, innovative leadership, and robust global network position it for sustained growth and margin improvement. While inherent risks—such as economic sensitivity, regulatory challenges, and intensifying competition—warrant close monitoring, DENTSPLY SIRONA’s scale, recurring consumables business, and digital ecosystem offer meaningful strategic defensibility. For long-term investors, the company provides a balanced mix of growth, resilience, and exposure to enduring healthcare demand, anchored by an ability to capitalize on ongoing transformation within dental medicine.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For Q4 2025, XRAY reported revenue of $961 million, a net loss of $145 million, and an EPS of -$0.73. Despite negative net income, the company generated a positive free cash flow of $60 million. Year-over-year growth metrics were not indicated, suggesting the focus is on recent quarterly performance. XRAY's revenue indicated robustness in the industry despite the quarter's financial losses. Profitability is under pressure, as indicated by a negative net margin, stressing the need for restructuring or operational improvements. On the balance sheet, XRAY maintains total assets of $5.43 billion and liabilities of $4.09 billion, leading to equity of $1.34 billion. Net debt stands at $2.095 billion, indicating leverage that may need addressing, yet the company holds $326 million in cash, providing some liquidity buffer. With a share count of approximately 199.6 million, maintaining stable dividend payments at $0.16 aligns with shareholder return strategies. Analysts have set a consensus price target of $13.33, with sentiment reflecting moderate caution given the financial backdrop."

Revenue Growth

Neutral

Despite losses, revenue of $961 million signifies potential stability in product demand or market position.

Profitability

Neutral

Net income of -$145 million and EPS of -$0.73 reflect negative margins and room for operational improvements.

Cash Flow Quality

Neutral

Positive free cash flow of $60 million highlights cash generation, although dividends outpace net income.

Leverage & Balance Sheet

Fair

Net debt is substantial at $2.095 billion with D/E ratio over 1.5, warranting cautious leverage management.

Shareholder Returns

Fair

Dividend consistency at $0.16 per quarter is supportive, yet capital returns are limited by net income.

Analyst Sentiment & Valuation

Fair

With a consensus price target of $13.33, market sentiment is cautiously neutral, reflecting balanced risk and opportunity.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So what: management is messaging a credible “Return to Growth” transformation for 2026 (sales $3.5B–$3.6B; EPS $1.40–$1.50) but the Q&A highlights execution timing headwinds and balance-sheet discipline. They quantified tariff damage (Q4 gross profit $15M headwind; 2025 $23M) and connected it to a $144M net-of-tax impairment in CTS/OIS—tied to tariffs and volume declines under competitive pressure. Operationally, the dealer model change introduces a near-term timing drag: management estimated about ~$30M in inventory sell-through in 1H and targeting a full drop-ship model by Q4. Capital allocation is also constrained: dividend elimination frees ~$128M annually, but repurchases are contingent on first retiring debt to protect investment-grade status. While Dan projects urgency and some sequential improvement starting in 3Q, analyst pressure focused on whether partnership/dealer actions translate into dollars in guidance (not “major” in guide) and on the near-term magnitude/timing of inventory and investment ramps.

AI IconGrowth Catalysts

  • Wellspect Surity female external catheter launch (new noninvasive solution for urinary incontinence)
  • Bringing CEREC onto DS Corp (workflow efficiency)
  • Increased R&D investment by double digits in 2026 to accelerate DS core, EDS, implants and ortho
  • U.S. turnaround: reorganized/unified commercial teams; new North America sales leadership (Mark Bezjak hire)
  • Dealer-channel re-engagement in CTS via expanded agreements (aims to broaden reach and penetration)
  • Transformation office to run enterprise AI strategy and lean operating principles

Business Development

  • Expanded/new partner agreements announced: Benco, Patterson, Burkhart, and A-dec (dealer/channel expansion in the U.S.)

AI IconFinancial Highlights

  • Q4 revenue: $961M (+6.2% reported; +2.5% constant currency vs prior year)
  • Constant-currency tailwinds: foreign currency +370 bps; onetime Byte customer refund + distributor pre-buys contributed ~570 bps tailwind to constant-currency growth
  • Adjusted EBITDA margin: declined 10 bps to 14.1% driven by ~300 bps gross profit decline (lower volume, sales mix, and tariff impacts)
  • Tariffs impact in Q4: ~$15M headwind to gross profit
  • Adjusted EPS: $0.27, up $0.01 (+4.9%) vs prior year
  • Noncash impairment charge in Q4: $144M net of tax (goodwill and intangibles) in CTS and OIS segments; attributed to tariffs and volume declines reflecting competitive pressures
  • Q4 operating cash flow: $101M; free cash flow: $60M; cash & cash equivalents: $326M; net debt-to-EBITDA: 3.0
  • Full-year 2025: sales $3.68B (-3% reported; -4.3% constant currency); adjusted EPS $1.60 (-4.6% y/y) with higher tax rate
  • Full-year 2025 tariffs: $23M headwind to gross profit
  • Full-year dividend: $128M (Q4 dividend paid: $32M)

AI IconCapital Funding

  • Dividend elimination: management stated ~$128M annually freed up for debt retirement and share repurchases
  • Planned order of operations: prioritize debt retirement to avoid falling below investment grade, then repurchase shares (no specific timing/price levels disclosed beyond 'attractive stock price')
  • Share repurchase approach: no structured cadence mentioned; repurchases targeted at 'bargain' pricing when execution permits

AI IconStrategy & Ops

  • Restructuring program expected to unlock ~($120M) annually across the P&L to fund Return to Growth investments
  • Restructuring nonrecurring charges expected: $55M to $65M (majority expensed and paid in cash in 2026 and 2027)
  • Manufacturing/distribution network actions: consolidate resources, standardize packaging, implement advanced planning/forecasting to improve working capital and reduce product cost
  • Dealer inventory model change (U.S.): shift from selling into dealer inventory to a drop-ship model
  • Drop-ship transition timing (per Q&A): targeted to be in full drop-ship with all vendors by Q4; first-half inventory sell-through estimate ~ $30M headwind (timing vs structural not quantified beyond the described mechanism)
  • Commercial org timing (per Q&A): reorganization 'done' and active end of Q1; benefits expected into March/April

AI IconMarket Outlook

  • 2026 net sales guidance: $3.5B to $3.6B (operational growth -3% to -1%)
  • 2026 sequential momentum expectation: positive sequential sales momentum in 2H 2026 (no quarterly guidance)
  • 2026 headwinds explicitly excluded from operational growth: -2.1% 2025 Byte headwind and 2026 one-time dealer capital equipment inventory sell-through (working with dealer partners and adjusting inventory models)
  • 2026 adjusted EPS guidance: $1.40 to $1.50 (reflects accelerated investments: innovation, clinical education, Wellspect penetration, and commercial investments)
  • R&D investment intensity framing (per Q&A): R&D around ~4% in 2025; expected to rise to ~5% in 2026; potential 'in the sights' but not committed to ~6%

AI IconRisks & Headwinds

  • Tariff pressure: ~$15M gross profit headwind in Q4; ~$23M gross profit headwind across 2025; impairment charge ($144M net of tax) partially driven by tariffs
  • Volume declines across major areas: management cited lower volumes for CAD/CAM and implants across all regions as the largest 2025 challenges
  • Competitive pressures: explicitly cited as a driver of volume declines contributing to the impairment
  • Byte wind-down: full-year EPS included ~$0.13 income from Byte; Byte income will not recur and is a headwind going forward (timed to wind down in Q1 2026)
  • U.S. operational transition risk: dealer capital equipment inventory model and drop-ship transition can create timing headwinds (estimated ~$30M sell-through/inventory impact in 1H)
  • China procurement behavior risk: in implants, expectations for the second phase of volume-based procurement in 2026 shifted buying behavior, leading to a double-digit decline in 2H 2025 second-half expectation

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the XRAY Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (XRAY)

© 2026 Stock Market Info — DENTSPLY SIRONA Inc. (XRAY) Financial Profile